Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7888328 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(6 days ago) | |
US8785415 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(6 days ago) | |
US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(2 years from now) | |
US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(2 years from now) | |
US10849919 | EMD SERONO INC | Cladribine regimen for treating progressive forms of multiple sclerosis |
Nov, 2038
(14 years from now) |
Mavenclad is owned by Emd Serono Inc.
Mavenclad contains Cladribine.
Mavenclad has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Mavenclad are:
Mavenclad was authorised for market use on 29 March, 2019.
Mavenclad is available in tablet;oral dosage forms.
Mavenclad can be used as treating non-early spms by administering oral cladribine at a fixed dose per patient, per body weight and per treatment year, which fixed dose is 1.75 +/- 0.2 mg/kg, to be administered within months 1 and 2 in each of 2 adjacent treatment years, treating ms with oral cladribine acc. to the steps (i) induction period with about 1.7 mg/kg-3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) maintenance period with about 1.7 mg/kg cladribine; (iv) cladribine-free period, treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1.7 mg/kg cladribine; (iv) cladribine-free period, treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda, treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w.
The generics of Mavenclad are possible to be released after 23 November, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...
Dosage: TABLET;ORAL